Dr. Sebastian Lobentanzer is a seasoned biomedical researcher and research software engineer with extensive expertise in systems pharmacology. Having completed a PhD in pharmacology and toxicology, he is particularly interested in disentangling causal relationships in molecular biology. He has pursued this focus as a postdoctoral researcher in the lab of Julio Saez-Rodriguez at Heidelberg University Hospital from 2021 to 2025 and, since 2024, in affiliation with the Open Targets group at the European Bioinformatics Institute (EMBL-EBI). Since 2025, he is a Principal Investigator at Helmholtz Munich and leads the Computational Biology Unit at the German Centre for Diabetes Research.